Indian markets closed lower on Thursday as investors reacted to US President Donald Trump's announcement of a 26% tariff on Indian exports.
However, the exclusion of pharmaceutical products from the tariff list resulted in a rally in domestic pharma stocks, given the sector's significant exposure to the US market.
The BSE Sensex declined 322.08 points, or 0.4%, to 76,295.36, while the NSE Nifty 50 dropped 82.25 points, or also 0.4%, to 23,250.10.
Tata Consultancy Services (NSE:TCS, BOM:532540) led the laggards, falling 4%, followed by HCLTech (NSE:HCLTECH, BOM:532281) and Tech Mahindra (NSE:TECHM, BOM:532755).
Power Grid Corp. of India (NSE:POWERGRID, BOM:532898), Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715), and Cipla (NSE:CIPLA, BOM:500087) were the top gainers.
In corporate updates, Bajaj Finance (NSE:BAJFINANCE, BOM:500034) raised 59.9 billion rupees Indian via the allotment of non-convertible debentures in two tranches, according to a Thursday filing. The securities will be listed on the BSE Wholesale Debt Market Segment.
Meanwhile, Gland Pharma (NSE:GLAND, BOM:543245) received US FDA approval for Acetaminophen injection bags, a bioequivalent and therapeutically equivalent alternative to B. Braun Medical's reference drug.
Comments